Table 2.
Summary of responses: randomized population
Responses, n (%) | Varlitinib + capecitabine (n = 64) | Placebo + capecitabine (n = 63) |
---|---|---|
Objective response | 6 (9.4) | 3 (4.8) |
Complete response | 0 (0) | 0 (0) |
Partial response | 6 (9.4) | 3 (4.8) |
Stable disease | 29 (45.3) | 34 (54.0) |
Progressive disease | 24 (37.5) | 24 (38.1) |
Early death | 4 (6.3) | 0 (0) |
RECIST v1.1 progression | 20 (31.3) | 24 (38.1) |
Non-evaluable | 5 (7.8) | 2 (3.2) |